Protective capabilities of IL-2 in recovery after traumatic brain injury in animals of different ages

Abstract

Introduction. Elder age is a significant negative health factor after traumatic brain injury (TBI).

Aim was to study the dynamics of the brain-derived neurotrophic factor (BDNF) level, immune and hormonal disturbances that develop in young and elderly rats during the recovery period after TBI with the correction by recombinant interleukin (IL)-2 (rIL-2).

Material and methods. The work was performed on male Wistar rats aged 3 (young) and 18 months (elderly). The «weight drop» model was used as a model for TBI. To correct disturbances caused by TBI animals were medicated with commercial recombinant rIL-2 («Biotech», Russian Federation) in dose of 30 mcg/kg of body weight after the TBI once a day for 3 days. Control animals were injected with 0.15 М NaCl. On days 7 and 14 after TBI, the concentrations of corticosterone, testosterone and BDNF in the blood of animals were determined by ELISA; the activity of immune cells was determined by their cytotoxicity and proliferative activity.

Results. In intact and injured animals, both young and elderly, increased concentrations of corticosterone and testosterone were observed after administration of rIL-2 compared to animals not receiving rIL-2. Administration of rIL-2 to intact young and elderly animals did not change the BDNF concentration. TBI led to a significant decrease in BDNF levels in young and old animals, but BDNF levels significantly increased after rIL-2 administration in TBI groups (in both groups p < 0.05). After TBI the proliferative activity of splenocytes in young rats did not decrease, while in elderly rats the inhibition of the proliferative activity of splenocytes was significant (the stimulation index was below one). Administration of rIL-2 did not change the proliferative activity of splenocytes in young intact and injured rats. In elderly animals, a significant increase of suppressed proliferative splenocytes activity after TBI was observed; but in intact animals, the proliferative activity of lymphocytes did not change. TBI led to inhibition of the cytotoxic activity of splenocytes in young and elderly animals; the administration of rIL-2 increased it in injured rats, but did not change it in intact young and elderly rats.

Conclusion. rIL-2 in significand degree reversed the posttraumatic changes. Thus, exogenic rIL-2 may to some degree mitigate elder-age-related disfunctions caused and boosted by TBI.

Keywords:traumatic brain injury; IL-2; corticosterone; testosterone; brain-derived neurotrophic factor; splenocytes; proliferation; cytotoxicity

For citation: Serebryanaya N.B., Fomicheva E.E., Filatenkova T.A., Shanin S.N. Protective capabilities of IL-2 in recovery after traumatic brain injury in animals of different ages. Immunologiya. 2020; 41 (6): 519-26. DOI: https://doi.org/10.33029/0206-4952-2020-41-6-519-526 (in Russian)

Funding. The study had no sponsor support.

Conflict of interests. The authors declare no conflict of interests.

References

1. Gardner R.C., Dams-O'Connor K., Morrissey M.R., Manley G.T. Geriatric traumatic brain injury: epidemiology, outcomes, knowledge gaps, and future direction. J Neurotrauma. 2018; 35 (7): 889–906. DOI: https://doi.org/10.1089/neu.2017.5371

2. Sochocka M., Diniz B.S., Leszek J. Inflammatory response in the CNS: friend or foe? Mol Neurobiol. 2017; 54 (10): 8071–89. DOI: https://doi.org/10.1007/s12035-016-0297-1

3. Gong Z., Liu T., Wan Y., Hang Z., Tong X., Zhang B., Yang H., Zhang X., Zhang L., Jin G. Decreased c-rel activation contributes to aberrant interleukin-2 expression in CD4(+)T cells of aged rats. Mol Immunol. 2014; 61 (1): 1–6. DOI: https://doi.org/10.1016/j.molimm.2014.04.010

4. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192 (12): 5451–8. DOI: https://doi.org/10.4049/jimmunol. 1490019 PMID: 24907378.

5. Tahvildari M., Dana R. Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases. J Immunol. 2019; 203 (11): 2749–55. DOI: https://doi.org/10.4049/jimmunol.1900733

6. Sun L., Hurez V.J., Thibodeaux S.R., Kious M.J., Liu A., Lin P., Murthy K., Pandeswara S., Shin T., Curiel T.J. Aged regulatory T cells protect from autoimmune inflammation despite reduced STAT3 activation and decreased constraint of IL-17 producing T cells. Aging Cell. 2012; 11 (3): 509–19. DOI: https://doi.org/10.1111/j.1474-9726.2012.00812.x

7. Li M., Lin Y.P., Chen J.L., Li H., Jiang R.C., Zhang J.N. Role of regulatory T cell in clinical outcome of traumatic brain injury. Chin Med J (Engl). 2015; 128 (8): 1072–8. DOI: https://doi.org/10.4103/0366-6999.155094

8. Sennikov S.V., Khantakova J.N. Role of T-cell subpopulations in the immunologic tolerance induction. Immunology. 2017; 38 (4): 239–44. DOI: http://dx.doi.org/10.18821/0206-4952-2017-38-4-239-244

9. Leonov A.V. Cerebral blood flow in severe traumatic brain injuries. General Reanimatology. 2008; 4 (2): 9–13. URL: https://cyberleninka.ru/article/n/mozgovoy-krovotok-pri-tyazhelyh-cherepno-mozgovyh-travmah (in Russian)

10. Failla M.D., Kumar R.G., Peitzman A.B., Conley Y.P., Ferrell R.E., Wagner A.K. Variation in the BDNF gene interacts with age to predict mortality in a prospective, longitudinal cohort with severe TBI. Neurorehabil Neural Repair. 2015; 29 (3): 234–46. DOI: https://doi.org/10.1177/1545968314542617

11. Fomicheva E.E., Shanin S.N., Filatenkova T.A., Serebryanaya N.B. IL-2 and regulation of stress hormones and BDNF neurotropic factor levels after experimental traumatic brain injury (TBI). Medical Immunology (Russia). 2020; 22 (4): 647–56. DOI: https://doi.org/10.15789/1563-0625-IAR-1973 (in Russian)

12. Serebryanaya N.B., Lipatova L.V., Sivakova N.A., Vasilenko A.V. Recombinant human interleukin IL-2 as an agent of antiepileptic therapy. Russian Journal of Immunology. 2014; 8 (3): 723–6. URL: https://www.elibrary.ru/download/elibrary_22813217_25671670.pdf(in Russian)

13. Babichev V.N. Neuroendocrine effect of sex hormones. Advances in physiological sciences. 2005; 36 (1): 54–67. URL: https://www.elibrary.ru/item.asp?id=9139556 (in Russian)

14. Beloshitskiy V.V. Principles of modeling traumatic brain injury in experiment. UNJ. 2008; (4): 9–15. URL: https://cyberleninka.ru/article/n/printsipy-modelirovaniya-cherepno-mozgovoy-travmy-v-eksperimente (in Russian)

15. Saleem B.N., Ghirmay K., Kahase M. In silico comparison of interleukin-2 of Homo sapiens with different species. Pharma Focus: ERIPA. 2011; 14: 32–7. URL: https://www.academia.edu/1153368/N_Saleem_Basha_Kewani_Ghirmay_and_Melles_Kahsase_In_silico_comparison_of_interleukin_2_of_Homo_sapiens_with_different_species_Pharma_Focus_The_journal_of_Eritrean_Pharmaceutical_Association_ERIPA_Vol_14_Dec_10_2011_pp32_37

16. Lo M.J., Kau M.M., Cho W.L., Wang P.S. Aging effects on the secretion of corticosterone in male rats. J Investig Med. 2000; 48 (5): 335–42. PMID: 10979238.

17. de Assis G.G., Gasanov E.V. BDNF and cortisol integrative system – plasticity vs. degeneration: implications of the Val66Met polymorphism. Front Neuroendocrinol. 2019; 55: 100784. DOI: https://doi.org/10.1016/j.yfrne.2019.100784

18. Munoz M.J., Kumar R.G., Oh B.M., Conley Y.P., Wang Z., Failla M.D., Wagner A.K. Cerebrospinal fluid cortisol mediates brain-derived neurotrophic factor relationships to mortality after severe TBI: a prospective cohort study. Front Mol Neurosci. 2017; 10: 44. DOI: https://doi.org/10.3389/fnmol.2017.00044

19. Ostrova I.V., Avrushchenko M.S. Expression of brain-derived neurotrophic factor (BDNF) increases the resistance of neurons to death in the postresuscitation period. General Reanimatology. 2015; 11 (3): 45–53. DOI: https://doi.org/10.15360/1813-9779-2015-3-45-53 (in Russian)

20. Simon D., Nascimento R.I., Filho E.M., Bencke J., Regner A. Plasma brain-derived neurotrophic factor levels after severe traumatic brain injury. Brain Inj. 2016; 30 (1): 23–8. DOI: https://doi.org/10.3109/02699052.2015.1077993

21. Kalish H., Phillips T.M. Analysis of neurotrophins in human serum by immunoaffinity capillary electrophoresis (ICE) following traumatic head injury. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. 15; 878 (2): 194–200. DOI: https://doi.org/10.1016/j.jchromb.2009.10.022

22. Camous X., Pera A., Solana R., Larbi A. NK cells in healthy aging and age-associated diseases. J Biomed Biotechnol. 2012; 195956. DOI: https://doi.org/10.1155/2012/195956

23. Abbas A.K., Trotta E., Simeonov D., Marson A., Bluestone J.A. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol. 2018; 3 (25): eaat1482. DOI: https://doi.org/10.1126/sciimmunol.aat1482

24. Abel A.M., Yang C., Thakar M.S., Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018; 9: 1869. DOI: https://doi.org/10.3389/fimmu.2018.01869

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»